Chaincode Labs

Companies

Chaincode Labs is a Bitcoin-focused research and development lab founded in 2014, widely regarded as one of the most important contributors to Bitcoin Core development. The company employs and funds some of the most prolific Bitcoin protocol developers, including contributors behind SegWit, Taproot, Schnorr signatures, and Lightning Network research. Chaincode also runs the Chaincode Residency program, bringing together Bitcoin developers from around the world for intensive protocol education. It is a private company with no outside investment, committed to open-source Bitcoin development.

Details

Ceo: Alex Morcos
Public: No
Sector: bitcoin_infrastructure
Known For: Employs Bitcoin Core developers; runs Chaincode Residency; funded SegWit, Taproot, Lightning research
Company Type: Bitcoin Research & Development (Non-Profit)
Founded Year: 2014
Headquarters: New York, USA
Bitcoin Strategy: Bitcoin protocol research organization. Runs the Bitcoin Protocol Development fellowship and supports full-time Bitcoin Core and Lightning Network researchers.
Bitcoin Holdings Note: Non-profit research organization — does not hold Bitcoin treasury. Funds Bitcoin Core development.

Links

github twitter

More Companies

Strategy (formerly MicroStrategy)

Strategy (Nasdaq: MSTR), formerly MicroStrategy, is the world's largest corporate Bitcoin holder. Founded by Michael Saylor, the company rebranded in 2025 to reflect its identity as a Bitcoin treasury company. It holds over 500,000 BTC accumulated through equity and debt financing, pioneering the corporate Bitcoin standard that inspired hundreds of companies worldwide.

ACINQ

ACINQ is a French Bitcoin infrastructure company and the developer of Eclair, one of the three major Lightning Network implementations. Founded in 2014, ACINQ builds Phoenix Wallet (a non-custodial Lightning wallet) and operates the ACINQ Lightning node, one of the most well-connected nodes on the Lightning Network.

Acurx Pharmaceuticals

Acurx Pharmaceuticals (NASDAQ: ACXP) is a US biopharmaceutical company that made headlines in November 2021 by adopting Bitcoin as its primary treasury reserve asset — one of the first pharmaceutical companies to do so. The company approved purchasing $1 million in Bitcoin and has continued to hold BTC alongside its drug development pipeline focused on antibiotics. Notable for crossing industry boundaries to embrace the Bitcoin standard.